The American National Comprehensive Cancer Network (NCCN) guidelines recommend [18F]FDG PET/CT investigation starting at stage I (tumor larger than 1 cm and HER2 positive or triple negative) and stage IIA, regardless of histopathological subtype and prognosis [18]. The gene discussed is ERBB2; the disease is neoplasm.